Patterns of serum type 1 and type 2 immune markers in healthy carriers of HTLV-I

Journal of Medical Virology

Volumn 78, Issue 6, 2006, Pages 847-852

  Birmann, Brenda M ^a   Mueller, Nancy E ^a   Okayama, Akihiko ^b   Hsieh, Chung Cheng ^a,c   Tsubouchi, Hirohito ^b,e   Harn, Donald ^a   Stuver, Sherri O ^a,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Epidemiology; Epstein Barr virus antibodies; Immune deficiency; sCD23; sCD30; Total IgE

Indexed keywords

BIOLOGICAL MARKER; CD23 ANTIGEN; CD30 ANTIGEN; IMMUNOGLOBULIN E; SOLUBLE CD23 ANTIGEN; SOLUBLE CD30 ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ARTICLE; CELLULAR IMMUNITY; CELLULAR IMMUNODEFICIENCY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMORAL IMMUNE DEFICIENCY; HUMORAL IMMUNITY; IMMUNE DYSREGULATION; IMMUNOGLOBULIN BLOOD LEVEL; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; NORMAL HUMAN; VIRUS CARRIER;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, CD30; CARRIER STATE; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HTLV-I INFECTIONS; HUMANS; IMMUNOGLOBULIN E; LINEAR MODELS; RECEPTORS, IGE;

HUMAN HERPESVIRUS 4; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 33646486885     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20633     Document Type: Article

References (31)

1. Bansal AS, Ollier W, Marsh MN, Pumphrey RSH, Wilson PB. 1993. Variations in serum sCD23 in conditions with either enhanced humoral or cell-mediated immunity. Immunology 79:285-289.
2. Bengtsson Å, Holm L, Bäck O, Fransson J, Scheynius A. 1997. Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD). Clin Exp Immunol 109:533-537.
3. Birmann B, Mueller N, Okayama A, Hsieh CC, Tachibana N, Tsubouchi H, Lennette ET, Harn D, Stuver S. 2004. Serologic assessment of type 1 and type 2 immunity in healthy Japanese adults. Cancer Epidemiol Biomarkers Prev 13:1385-1391.
4. Cann AJ, Chen ISY. 1996. Human T-cell leukemia viruses types I and II. In: Fields BN, Knipe DM, Howley PM, et al., editors. Fields virology, 3rd edition. Philadelphia: Lippincott-Raven Publishers. pp 1849-1880.
5. Carvalho EM, Bacellar O, Porto AF, Braga S, Galvão-Castro B, Neva FA. 2001. Cytokine profile and immunomodulation in asymptomatic human T-lymphotropic virus type 1-infected blood donors. J Acquir Immune Defic Syndr 27:1-6.
6. D'Elios MM, Romagnani P, Scaletti C, Annunziato F, Manghetti M, Mavilia C, Parronchi P, Pupilli C, Pizzolo G, Maggi E, Del Prete GF, Romagnani S. 1997. In vivo CD30 expression in human diseases with predominant activation of Th2-like cells. J Leuk Biol 61:539-544.
7. Dallenbach F, Josimovic-Alasevic O, Dürkop H, Schwarting R, Diamantstein T, Matsuoka M, Takatsuki K, Stein H. 1989. Soluble CD30 antigen in the sera of patients with adult T-cell lymphoma/ leukemia (ATL): A marker for disease activity. In: Knapp W, Dorken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, von dem Borne AEG, editors. Leucocyte typing IV. Oxford, UK: Oxford University, pp 426-428.
8. Del Prete G, Maggi E, Romagnani S. 1994. Human Th1 and Th2 cells: Functional properties, mechanisms of regulation, and role in disease. Lab Invest 70:299-306.
9. Delespesse G, Suter U, Mossalayi D, Bettler B, Sarfati M, Hofstetter H, Kilcherr E, Debre P, Dalloul A. 1991. Expression, structure and function of the CD23 antigen. Adv Immunol 49:149-191.
10. Hayashi J, Kishihara Y, Yoshimura E, Furusyo N, Yamaji K, Kawakami Y, Murakami H, Kashiwagi S. 1997. Correlation between human T cell lymphotropic virus type-I and Strongyloides stercoralis infections and serum immunoglobulin E responses in residents of Okinawa, Japan. Am J Trop Med Hyg 56:71-75.
11. Henle W, Henle G. 1981. Epstein-Barr virus-specific serology in immunologically compromised individuals. Cancer Res 41:4222-4225.
12. Henle W, Henle G, Horwitz CA. 1974. Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Hum Pathol 5:551-565.
13. Hisada M, Shima T, Okayama A, Mueller N, Tsubouchi H, Stuver S. 1998. Suppression of skin reactivity to purified protein derivative by hepatitis C virus among HLTV-I carriers in Japan. J Aquir Immune Defic Syndr Hum Retrovirol 19:421-425.
14. Hisada M, Stuver SO, Okayama A, Mueller NE. 1999. Gender differences in skin reactivity to purified protein derivative among carriers of HTLV-I in Japan. J Acquir Immune Defic Syndr 22:302-307.
15. Imai J, Hinuma Y. 1983. Epstein-Barr virus-specific antibodies in patients with adult T-cell leukemia (ATL) and healthy ATL virus-carriers. Int J Cancer 31:197-200.
16. Katoh N, Hirano S, Suehiro M, Ikenaga K, Yamashita T, Sugawara N, Yasuno H. 2000. Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26. Clin Exp Immunol 121:187-192.
17. Kwon K. 1995. Epstein-Barr virus-specific immunity in asymptomatic carriers of human T-cell leukemia virus type 1. Hokkaido J Med Sci 70:315-328.
18. Lennette ET, Rymo L, Yadav M, Masucci G, Merk K, Timar L, Klein G. 1993. Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6. Eur J Cancer 29A:1584-1589.
19. Lucey DR, Clerici M, Shearer GM. 1996. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9:532-562.
20. Marsh BJ. 1996. Infectious complications of human T-cell leukemia/ lymphoma virus type I infection. Clin Infect Dis 23:138-145.
21. Matsumoto M, Miike T, Mizoguchi K, Yamaguchi K, Takatsuki K, Hosoda M, Kawabe T, Yodoi J. 1990. Decreased serum levels of IgE and IgE-binding factors in individuals infected with HTLV-I. Clin Exp Immunol 81:207-211.
22. Mueller N, Okayama A, Stuver S, Tachibana N. 1996. Findings from the Miyazaki Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 13:S2-S7.
23. Murai K, Tachibana N, Shioiri S, Shishime E, Okayama A, Ishizaki J, Tsuda K, Mueller N. 1990. Suppression of delayed-type hypersensitivity to PPD and PHA in elderly HTLV-I carriers. J Acquir Immune Defic Syndr 3:1006-1009.
24. Murphy EL, Glynn SA, Fridey J, Smith JW, Sacher RA, Nass CC, Ownby HE, Wright DJ, Nemo GJ, The Retrovirus Epidemiology Donor Study. 1999. Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Arch Intern Med 159:1485-1491.
25. Okayama A, Stuver S, Iga M, Okamoto M, Mueller N, Matsuoka M, Yamaguchi K, Tachibana N, Tsubouchi H. 2001. Sequential change of virus markers in seroconverters with community-acquired infection of human T-lymphotropic virus type I. J Infect Dis 183:1031-1037.
26. Pfreundschuh M, Berenbeck PC, Schroeder J, Jung W, Schmits R, Tschiersch A, Diehl V, Gause A. 1990. Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis. Int J Cancer 45:869-874.
27. Schroeder JR, Saah AJ, Hoover DR, Margolick JB, Ambinder R, Martínez-Maza O, Breen EC, Jacobson LP, Variakojis D, Rowe DT, Armenian HK. 1999. Serum soluble CD23 level correlates with subsequent development of AIDS-related non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 8:979-984.
28. Stein H, Mason DY, Gerdes J, O'Conner N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K. 1985. The expression of the Hodgkin's disease-associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that the Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848-858.
29. Tachibana N, Okayama A, Ishizaki J, Yokota T, Shishime E, Murai K, Shioiri S, Tsuda K, Essex M, Mueller N. 1988. Suppression of tuberculin skin reaction in healthy HTLV-I carriers from Japan. Int J Cancer 42:829-831.
30. Tendler CL, Greenberg SJ, Burton JD, Danielpour D, Kim SJ, Blattner WA, Manns A, Waldmann TA. 1991. Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: Alternate molecular mechanisms underlying retroviral pathogenesis. J Cell Biochem 46:302-311.
31. Whiteside TL. 1994. Cytokine measurements and interpretation of cytokine assays in human disease. J Clin Immunol 14:327-339.